Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
NASDAQ:GILD
Earnings Data
Report Date
Apr 24, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.77Last Year’s EPS
-1.32Same Quarter Last Year
Moderate Buy
Based on 25 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 11, 2025
|% Change Since: 14.45%
|Next Earnings Date:Apr 24, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong performance in key therapeutic areas, particularly in HIV and oncology, with successful product launches and promising pipeline developments. However, the company faces challenges from Medicare Part D reform, declining Veklury sales, and competitive pressures in cell therapies.Company Guidance
During Gilead's fourth quarter and full year 2024 earnings call, the company provided detailed guidance for 2025, emphasizing continued revenue growth despite several anticipated headwinds. Total product sales for 2025 are projected to range from $28.2 billion to $28.6 billion, with sales excluding Veklury expected to be between $26.8 billion and $27.2 billion. Gilead's HIV sales showed significant growth in 2024, with an 8% increase to $19.6 billion, surpassing expectations. However, in 2025, HIV revenues are expected to remain flat due to the $900 million impact from Medicare Part D reform. The company anticipates strong demand-led volume growth will continue, with lenacapavir poised for a potential U.S. launch in mid-2025, and advancing its regulatory filings globally. Gilead's oncology segment, highlighted by Trodelvy's growth, and its liver disease portfolio, bolstered by Livdelzi's strong launch, are also expected to contribute to the company's growth trajectory. Despite challenges, Gilead maintains a stable expense outlook, with plans to hold R&D steady and reduce SG&A expenses, aiming for a non-GAAP diluted EPS between $7.70 and $8.10.Strong Revenue Growth
Total product sales, excluding Veklury, increased 8% year-over-year to $26.8 billion, with fourth quarter sales up 13% year-over-year to $7.2 billion. HIV sales grew 8% in 2024 to $19.6 billion, surpassing expectations.
HIV Market Leadership
Full year sales for Biktarvy grew 13%, capturing over 50% of the U.S. market. Descovy maintained over 40% U.S. market share in PrEP, showing strong growth despite competition.
Successful Launch of Livdelzi
Livdelzi, launched in the United States for primary biliary cholangitis, achieved strong sales of approximately $30 million in the fourth quarter, exceeding expectations.
Oncology Growth
Trodelvy sales increased 19% year-over-year in the fourth quarter, with a full year increase of 24% to $1.3 billion. Cell therapy sales for Kite reached $2 billion, treating over 7,000 patients in 2024.
Pipeline Advancements
Gilead filed for lenacapavir approval for HIV prevention and achieved a breakthrough therapy designation. The company also highlighted progress in oncology trials and new cell therapy initiatives.
---
GILD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GILD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 11, 2025 | $96.14 | $103.31 | +7.46% |
| Nov 06, 2024 | $90.92 | $97.08 | +6.78% |
| Aug 08, 2024 | $74.26 | $72.37 | -2.55% |
| Apr 25, 2024 | $63.35 | $63.50 | +0.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Gilead Sciences (GILD) report earnings?
Gilead Sciences (GILD) is schdueled to report earning on Apr 24, 2025, TBA Not Confirmed.
What is Gilead Sciences (GILD) earnings time?
Gilead Sciences (GILD) earnings time is at Apr 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GILD EPS forecast?
GILD EPS forecast for the fiscal quarter 2025 (Q1) is 1.77.
---